Series A funding invested by Legend Capital & Legend Star (¥25 M)
September 2015
Moved in a new research and development Lab with 800m2 SPF animal facility and a 400m2 cell culture room. Located in PKU Healthcare Industrial Park.
February 2017
Series B funding lead by Panlin Capital (¥50 M)
April 2017
Sponsored Clinical Trial (investigator-initiated trial, IIT) “Rapid screening for individualized chemotherapy optimization of colorectal cancer with a novel conditional reprogramming technology-based functional diagnostic assay.”
August 2017
Launched new i-CR® technology platform Lauched RUO products for primary tumor cell: storage, isolation, in vitro culture and drug testing.
January 2018
Cothera Bioscience, Inc.Angel Investment ($5.5M).
May 2019
Restructured Cothera-Percans company builded an international team and an advanced basic research platform.
November 2019
License in PC-002
December 2020
Cothera Bioscience completed the series-B financing, and obtained USD 30 million of investment
June 2021
Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test Its Targeted MYC Mutation Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma
September 2021
License in CDK inhibitor Zotiraciclib
September 2021
Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test PC-002 for the Treatment of Neuroendocrine Prostate Cancer (NEPC)
March 2022
The NMPA has approved a Phase II clinical trial of PC-002 for high-grade B-cell lymphoma